Beam Therapeutics (BEAM) Depreciation & Amortization (CF) (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $5.6 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $5.6 million, up 1.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.4 million (up 1.58% YoY), and the FY2025 annual result was $22.3 million, up 1.68% from the prior year.
• Depreciation & Amortization (CF) eased to $5.6 million in Q1 2026 per BEAM's latest filing, from $5.7 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $5.7 million in Q4 2025 and troughed at $3.3 million in Q1 2022.
• A 5-year average of $4.9 million and a median of $5.4 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) jumped 136.91% in 2022, then slipped 0.68% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.9 million in 2022, then surged by 35.95% to $5.4 million in 2023, then advanced by 1.51% to $5.4 million in 2024, then grew by 4.13% to $5.7 million in 2025, then retreated by 1.11% to $5.6 million in 2026.
• Business Quant data shows BEAM's Depreciation & Amortization (CF) at $5.6 million in Q1 2026, $5.7 million in Q4 2025, and $5.6 million in Q3 2025.